Neuland Laboratories Limited (NEULANDLAB)

Name: Neuland Laboratories Limited (NEULANDLAB) — histórico de demonstrações financeiras
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

Histórico de receita, lucros e fluxo de caixa das demonstrações financeiras oficiais.

Healthcare · Wall Street (EUA) · Última atualização: 2026-09-20

Neuland Laboratories Limited engages in the manufacture and sale of active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. It also provides custom manufacturing solutions, generic drug substances, as well as peptide APIs and synthesis services. The company serves generic companies, regional and domestic pharmaceutical manufacturers, distributors, and other pharmaceutical and biotechnology companies. Neuland Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Números-chave

Capitalização de mercado: ₹293 billion
Receita (exercício encerrado em 2026-03-31): ₹19.3B
Lucro líquido: ₹3.6B
Margem bruta: 51.0%
Margem líquida: 18.8%

Ver gráficos interativos e demonstrações completas →

Demonstração de resultados anual

Demonstração de resultados	2026-03-31	2025-03-31	2024-03-31	2023-03-31
Receita total	₹19.3B	₹14.3B	₹15.2B	₹11.6B
Lucro bruto	₹9.8B	₹6.8B	₹7.8B	₹5.5B
Resultado Operacional (EBIT)	₹4.9B	₹2.7B	₹4.1B	₹2.3B
Resultado líquido	₹3.6B	₹2.6B	₹3.0B	₹1.6B

Fonte: relatórios públicos da empresa (SEC). Verifique no SEC EDGAR antes de confiar em qualquer número.

Balanços, fluxos de caixa, dados trimestrais e indicadores completos no visualizador interativo de NEULANDLAB. /companies/us/NEULANDLAB

Empresas semelhantes

As informações deste site são apenas educacionais e informativas; não constituem recomendação de investimento. Não publicamos preços-alvo nem recomendações.

English version →Todas as ações

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.